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Statement of findings
Interferon-g was measured in supernatants after in vitro stimulation of peripheral blood
mononuclear cells with collagen type II (CII), purified protein derivative or influenza virus.
Interferon-g production in response to CII was similar in rheumatoid arthritis (RA) patients
and healthy control individuals. The interferon-g response to purified protein derivative and
influenza virus was lower in RA patients, reflecting a general T-cell hyporesponsiveness in
RA. After recalculating the response to CII taking this hyporesponsiveness into account the
CII response was higher in RA patients, and was associated with human leucocyte antigen
(HLA)-DRB1*0401 and HLA-DQA1*0301-DQB1*0302 (HLA-DQ8). Rheumatoid arthritis
patients with elevated serum levels of immunoglobulin (Ig)G anti-CII antibodies had lower
CII-induced interferon-g production than patients with low anti-CII levels. The relative
increase in CII-reactivity in RA patients as compared with healthy control individuals, and the
association of a higher response with RA-associated HLA haplotypes, suggest the existence
of a potentially pathogenic cellular reactivity against CII in RA.
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CII = collagen type II; HLA = human leucocyte antigen; HLA-DQ8 = HLA-DQA1*0301-DQB1*0302; Ig = immunoglobulin; MHC = major histo-
compatibility complex; PBMC = peripheral blood mononuclear cell; PBS = phosphate buffered saline; PPD = purified protein derivative;
RA = rheumatoid arthritis.
Introduction: Despite much work over past decades, whether
antigen-specific immune reactions occur in rheumatoid arthritis
(RA) and to what extent such reactions are directed towards joint-
specific autoantigens is still questionable. One strong indicator for
antigenic involvement in RA is the fact that certain major
histocompatibility complex (MHC) class II genotypes [human
leucocyte antigen (HLA)-DR4 and HLA-DR1] predispose for the
development of the disease [1]. In the present report, collagen
type II (CII) was studied as a putative autoantigen on the basis of
both clinical and experimental data that show an increased
frequency of antibodies to CII in RA patients [2–4] and that show
that CII can induce experimental arthritis [5].
It is evident from the literature that RA peripheral blood
mononuclear cells (PBMCs) respond poorly to antigenic
stimulation [6–8], and in particular evidence for a partial
tolerization to CII has been presented [9]. The strategy of the
present work has accordingly been to reinvestigate T-cell
reactivity to CII in RA patients, to relate it to the response to
commonly used recall antigens and to analyze interferon-g
responses as an alternative to proliferative responses.
Aims: To study cellular immune reactivity to CII in patients with
RA and in healthy control individuals and to correlate this
reactivity to HLA class II genotypes and to the presence of
antibodies to CII in serum.
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Methods: Forty-five patients who met the 1987 American
College of Rheumatology classification criteria for RA [10] and
25 healthy control individuals of similar age and sex were
included. Twenty-six of these patients who had low levels of
anti-CII in serum were randomly chosen, whereas 19 patients
with high anti-CII levels were identified by enzyme-linked
immunosorbent assay (ELISA)-screening of 400 RA sera.
Heparinized blood was density gradient separated and PBMCs
were cultured at 1 × 106/ml in RPMI-10% fetal calf serum with
or without antigenic stimulation: native or denatured CII
(100 mg/ml), killed influenza virus (Vaxigrip, Pasteur Mérieux,
Lyon, France; diluted 1:1000) or purified protein derivative
(PPD; 10 mg/ml). CII was heat-denatured in 56°C for 30 min.
Cell supernatants were collected after 7 days and interferon-g
contents were analyzed using ELISA. HLA-DR and HLA-DQ
genotyping was performed utilizing a polymerase chain
reaction-based technique with sequence-specific oligonucleo-
tide probe hybridization. Nonparametric statistical analyses
were utilized throughout the study.
Results: PBMCs from both RA patients and healthy control
individuals responded with inteferon-g production to the same
degree to stimulation with native and denatured CII (Fig. 1a),
giving median stimulation indexes with native CII of 4.6 for RA
patients and 5.4 for healthy control individuals, and with
denatured CII of 2.9 for RA patients and 2.6 for healthy control
individuals. RA patients with elevated levels of anti-CII had a
weaker interferon-g response to both native and denatured CII
than did healthy control individuals (P = 0.02 and 0.04,
respectively).
Stimulation with the standard recall antigens PPD and killed
influenza virus yielded a median stimulation index with PPD of
10.0 for RA patients and 51.3 for healthy control individuals and
with influenza of 12.3 for RA patients and 25.7 for healthy,
control individuals. The RA patients displayed markedly lower
responsiveness to both PPD and killed influenza virus than did
healthy control individuals (Fig. 1b). Interferon-g responses to all
antigens were abrogated when coincubating with antibodies
blocking MHC class II.
The low response to PPD and killed influenza virus in RA
patients relative to that of healthy control individuals reflects a
general downregulation of antigen-induced responsiveness of
T cells from RA patients [6–8]. That no difference between the
RA group and the control group was recorded in CII-induced
interferon-g production therefore indicates that there may be an
underlying increased responsiveness to CII in RA patients,
which is obscured by the general downregulation of T-cell
responsiveness in these patients. In order to address this
possibility, we calculated the fraction between individual values
for the CII-induced interferon-g production and the PPD-
induced and killed influenza virus-induced interferon-g
production, and compared these fractions. A highly significant
difference between the RA and healthy control groups was
apparent after stimulation with both native CII and denatured
CII when expressing the response as a fraction of that with
PPD (Fig. 2a). Similar data were obtained using killed influenza
virus-stimulated interferon-g values as the denominator (Fig.
2b).
When comparing the compensated interferon-g response to
denatured CII stimulation between RA patients with different
HLA genotypes, highly significant differences were evident,
with HLA-DRB1*0401 patients having greater CII
responsiveness than patients who lacked this genotype
(Fig. 3a). HLA-DQ8 positive patients also displayed a high
responsiveness to CII as compared with HLA-DQ8 negative
RA patients (Fig. 3b). These associations between the relative
T-cell reactivity to denatured CII and HLA class II genotypes
were not seen in healthy control individuals. Similar results
were achieved using influenza as denominator (P = 0.02 for
HLA-DRB1*0401 and P = 0.01 for HLA-DQ8).
Figure 1
Rheumatoid arthritis (RA) peripheral blood mononuclear cells (PBMCs)
respond similarly to collagen type II (CII) as healthy control individual
PBMCs, but they are hyporesponsive to other antigens. PBMCs from
RA patients (n = 45) and healthy control individuals (n = 25) were
stimulated with antigen for 7 days, and supernatants were analyzed by
enzyme-linked immunosorbent assay (ELISA) for concentration of
interferon-g. The background interferon-g production in wells without
added antigen was subtracted in each case. (a) Levels of interferon-g
after stimulation with native or denatured CII, and (b) after stimulation
with purified protein derivative (PPD) or killed influenza virus are
shown. The box plots show the median as a line and the 25th and 75th
centiles limiting the box, with the 10th and 90th centiles indicated with
bars.Discussion: No reports have previously systematically taken the
general T-cell hyporesponsiveness in RA into account when
investigating specific T-cell responses in this disease. In order to
address this issue we used the T-cell responses to PPD and killed
influenza virus as reference antigens. This was made on the
assumption that exposure to these antigens is similar in age-
matched and sex-matched groups of RA patients and healthy
control individuals. The concept of a general hyporesponsiveness
in RA T cells has been documented in several previous reports, in
which both nominal antigens [6–8] and mitogens [11–13] have
been used. The fact that a similar functional downregulation in RA
PBMCs was obtained with both PPD and killed influenza virus as
reference antigens strengthens the validity of our approach.
We identified an association between the interferon-g response
to CII and HLA-DRB1*0401 and HLA-DQ8 in the RA patient
group, which is of obvious interest because both these MHC
class II alleles have been associated with high responsiveness
to CII in transgenic mice that express these human MHC class
II molecules [14,15]. There was no association between high
anti-CII levels and shared epitope (HLA-DRB1*0401 or HLA-
DRB1*0404).
Conclusion: CII, a major autoantigen candidate in RA, can
elicit an interferon-g response in vitro that is associated with
HLA-DRB1*0401 and HLA-DQ8 in RA patients. This study,
with a partly new methodological approach to a classical
problem in RA, has provided some additional support to the
notion that CII may be a target autoantigen of importance for a
substantial group of RA patients. Continued efforts to identify
mechanisms behind the general hyporesponsiveness to
antigens in RA, as well as the mechanisms behind the potential
partial anergy to CII, may provide us with better opportunities
to study the specificity and pathophysiological relevance of
anti-CII reactivity in RA. 77
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Figure 2
After compensating for the antigen hyporesponsiveness, rheumatoid
arthritis (RA) peripheral blood mononuclear cells (PBMCs) had a
higher response to collagen type II (CII) than did healthy control
individual PBMCs. Production of interferon-g in RA patients (n = 45)
and healthy control individuals (n = 25) in response to stimulation with
native or denatured CII after compensation for the diminished
responsiveness in RA patients (a) for purified protein derivative (PPD)
and (b) for killed influenza virus are shown. On the y-axis the quotient
between the CII-induced interferon-g production and (a) the PPD-
induced interferon-g production and (b) the killed influenza virus-
induced interferon-g production is given. The box plots show the
median as a line and the 25th and 75th centiles limiting the box, with
the 10th and 90th centiles indicated with bars.
Figure 3
Rheumatoid arthritis (RA) patients with disease-associated human
leucocyte antigen (HLA) genotypes had a higher relative reactivity to
CII than RA patients with other HLA genotypes. Purified protein
derivative (PPD) compensated interferon-g production in response to
denatured type II collagen are shown: (a) HLA-DRB1*0401-positive
(n = 13) or DRB1*0401-negative (n = 32) RA patients and healthy
control individuals (n = 9 and 15, respectively); and (b) HLA-
DQA1*0301-DQB1*0301 (HLA-DQ8)-positive (n = 15) and HLA-
DQ8 negative (n = 30) RA patients and healthy control (HC)
individuals (n = 5 and 15, respectively). The box plots show the median
as a line and the 25th and 75th centiles limiting the box, with the 10th
and 90th centiles indicated with bars.Introduction
Despite much work over past decades, whether antigen-
specific immune reactions occur in rheumatoid arthritis (RA)
and to what extent such reactions are directed towards
joint-specific autoantigens is still questionable. The fact that
certain major histocompatibility complex (MHC) class II
genotypes [human leucocyte antigen (HLA)-DR4 and HLA-
DR1] predispose to the development of RA [1] points to the
possibility of antigenic involvement. The presence of an
increased frequency of autoantibodies to cartilage-specific
molecules such as collagen type II (CII) in RA [2–4] and the
fact that CII and other joint-derived proteins can cause
arthritis in experimental animals after immunization [5] indi-
cate a possible pathogenic role of autoimmune reactions
towards these molecules. It has been difficult, however, to
convincingly demonstrate cellular reactivity against joint-
derived autoantigens such as CII in RA. This has con-
tributed to the widespread notion that specific T-cell
reactivities may not be all that important in RA, and that
autoimmunity to joint antigens such as CII may only be of
importance in very limited subgroups of RA patients.
A few lines of partly new evidence have now led us to rein-
vestigate the issue of cellular reactivity to CII in RA. First,
there is increasing evidence that immunoreactivity to CII
can indeed be associated with the RA-associated HLA
allele DRB1*0401 and the closely linked allele
DQA1*0301-DQB1*0302 (HLA-DQ8). The best evidence
comes from studies in DRB1*0401 [14,16] or HLA-DQ8
[15] transgenic mice, which have a high susceptibility to
CII-induced arthritis. There are also studies of antibody
production to CII in joints that indicate that this is a rela-
tively common feature among RA patients [17,18] and is
associated with the presence of HLA-DR4 [18,19].
Second, at least two possible mechanisms by which an
existing T-cell responsiveness to CII may have remained
undetected using conventional methods (such as determi-
nation of proliferation in response to CII in vitro) have been
suggested. One mechanism may reside in the low T-cell
reactivity to recall antigens in RA patients as compared
with healthy control individuals [6–8]. Another mechanism
may reside in the partial tolerization to CII that can occur
in vivo, as reported in transgenic mice in which the DNA
sequence of an immunodominant peptide from rat CII was
expressed in the mouse CII gene [9]. In that study, T-cell
responses to the rat CII peptide was measured after
immunization of rat CII. Proliferative responses were not
detected but peptide-induced interferon-g production was
evident in vitro, indicating that the mouse was tolerized to
the antigen but that this tolerization only affected the pro-
liferative response.
The strategy behind the present work has accordingly
been to reinvestigate T-cell reactivity to CII in RA patients,
taking the potential partial tolerization of CII-specific T
cells and the general hyporesponsiveness of RA T cells
into consideration. We investigated interferon-g responses
after CII stimulation of peripheral blood mononuclear cells
(PBMCs) in vitro and compensated for the general T-cell
hyporesponsiveness by expressing the CII response as a
fraction of the response to standard recall antigens. We
also investigated possible associations of the recorded
cellular reactivity to CII with HLA genotypes. Finally, we
compared CII-induced interferon-g responses in RA
patients with and without antibodies to CII.
Materials and methods
Patients
Initially 400 RA patients, including both those with early
arthritis and those with more advanced stages of disease,
were screened for the occurrence of high levels of anti-
CII antibodies. From this screening 23 patients were
identified as having more than 15 U/ml anti-CII antibodies
[for definition of these units, see separate method descrip-
tion of CII enzyme-linked immunosorbent assay (ELISA)].
These patients were asked to return and participate in the
present study. Of these 19 also had elevated anti-CII
levels (> 9 U/ml) at inclusion into the study and comprised
the group of RA patients with high anti-CII levels (median
age 54 years, range 31–86 years). In addition, 26 RA
patients (median age 55 years, range 23–78 years) with
low anti-CII levels were randomly chosen. All patients met
the 1987 American College of Rheumatology classifica-
tion criteria for RA [10]. Twenty-five healthy staff members
of similar age and sex from the Department of Rheumatol-
ogy, Karolinska Hospital, served as healthy control individ-
uals. Informed consent was obtained from all patients and
control individuals included in the study. Patient character-
istics are given in Table 1.
Cell separation and stimulation
Peripheral blood was collected into heparinized tubes
and diluted 1:2 with phosphate buffered saline (PBS).
Mononuclear cells were isolated by density gradient cen-
trifugation and diluted to 1 × 106/ml in RPMI-1640 (Flow
Laboratories, Irvine, Scotland, UK) supplemented with
glutamine, HEPES buffer (Life Technologies, Paisley,
Scotland, UK), penicillin, streptomycin and 10% of a
defined batch of fetal calf serum (Flow Laboratories).
Chick CII (Sigma, St Louis, MO, USA) or human CII [a
kind gift from Alvar Grönberg (formerly Pharmacia),
Uppsala, Sweden] diluted in 0.1 mol/l acetic acid, or just
0.1 mol/l acetic acid as a buffer control, was added to
1 ml of the cell suspension, giving a final concentration of
100 mg/ml of CII and 2 mmol/l acetic acid. When stimu-
lating with denatured CII, a stock solution of CII was incu-
bated at 56°C for 30 min and then added to the cell
suspension.
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Full articleAs standard recall antigens, purified protein derivative
(PPD; Statens Smittskyddsinstitut, Solna, Sweden; final
concentration 10 mg/ml) and killed influenza virus (Vaxi-
grip, Pasteur Mérieux, Lyon, France; diluted 1:1000) was
added to 1 ml of the cell suspension.
For blocking of HLA class II antigens, three different sets
of antibodies were used in parallel: a mixture of 1 mg/ml of
each of three monoclonal antibodies: antibody 2.06 [anti-
DR, mouse immunoglobulin (Ig)G1], IVA12 (anti-DR, DP,
mouse IgG1) and 9.3F10 (anti-DR, DQ, mouse IgG2a; all
from ATCC, Rockville, Maryland, USA). This mixture of
anti-class II antibodies has earlier been described to
specifically block antigen-induced cytokine responses
[20]. As control, an isotype-weighted mixture of the
antikeyhole limpet haemocyanin monoclonal antibodies
HS (mouse IgG1 [21]) and 7B4 (mouse IgG2a [21]) were
used. In a second set of experiments, 10 mg/ml of L243
(mouse IgG1; ATCC [22]) were used with HS as control
antibody. In some confirmatory experiments 10 mg/ml of a
F(ab)¢2 rabbit polyclonal antibody against human class II
antigens were used with rabbit F(ab)¢2 antibody against
human IgG as control [23].
Cells were incubated in round bottomed 96-well plates
(NUNC A/S, Roskilde, Denmark) for 7 days using a proto-
col that has been optimized for antigen induced inter-
feron-g detection in supernatants ([24], our unpublished
data). Supernatants were collected and frozen at –20°C
for later analyses of cytokine content.
Interferon-g g measurements
ELISA plates (Maxisorp; NUNC A/S) were coated with
50 ml of 2 mg/ml catcher antibody (1-D1K; MabTech, Stock-
holm, Sweden) in PBS overnight at 4°C. After blocking the
plates with 100 ml PBS + 1% bovine serum albumin for 1 h
at room temperature, the plates were washed with PBS +
0.05% Tween. Recombinant interferon-g (R&D Systems,
Minneapolis, MN, USA) was diluted in medium and 50 ml of
samples and cytokine standards were added in duplicates.
The plates were incubated for 4 h at room temperature,
washed and 50 ml/well of a secondary biotinylated antibody
http://arthritis-research.com/content/2/1/075
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Table 1
Patient characteristics
Number Age Sex Disease Erosive
of subjects (years) (F/total) duration (years) CRP disease
All patients 45 55 34/45 10 15 27/42
(23–86) (76%) (0.5–30) (0–95) (64%)
Patients with 54 15/19 8 10 12/18
high anti-CII levels 19 (31–86) (79%) (0.5–30) (0–95) (67%)
Patients with low 26 55 19/26 12.5 20 15/24
anti-CII levels (23–78) (73%) (2.0–30) (0–62) (63%)
Healthy controls 25 51 22/25 – ND –
(36–61) (88%)
Number of Number of Mean daily
swollen tender NSAID Steroid prednisolone MTX DMARD
joints joints therapy therapy dosage therapy therapy
All patients 2 4 26/42 13/42 2.0 13/42 30/42
(0–17) (0–17) (62%) (31%) (31%) (71%)
Patients with 9 6 10/18 4/18 1.1 5/18 9/18
high anti-CII levels (0–17) (0–17) (56%) (22%) (28%) (50%)
Patients with low 2 3 16/24 9/24 2.7 8/24 21/24
anti-CII levels (0–15) (0–16) (67%) (38%) (33%) (88%)
Healthy controls – – – ––––
Data are given as median values and ranges for the various groups. Daily prednisolone dosages are presented as mean values in mg. Disease
modifying antirheumatic drugs (DMARDs) include sulfasalazin (0/18 high anti-CII patients treated, 6/24 low anti-CII patients treated,), cyklosporine
(1/18 high anti-CII, 1/24 low anti-CII), Reumacon (a podophyllin derivative, 1/18 high anti-CII, 1/24 low anti-CII), chloroquine (0/18 high anti-CII,
2/24 low anti-CII), aurathiomalase (0/18 high anti-CII, 3/24 low anti-CII), auranofin (1/18 high anti-CII, 0/24 low anti-CII) and azatioprin (1/18 high
anti-CII, 1/24 low anti-CII). Figures for sex distribution, erosiveness and medications are given both as fraction of number positive/number
investigated, and as percentage. Data on erosive disease are based on X-ray evaluations. Patient charts were not available for three patients, one
with high anti-CII levels and two with low anti-CII levels. F, female; CRP, C-reactive protein; NSAID, nonsteroidal anti-inflammatory drug; MTX,
methotrexate; ND, not done; CII, collagen type II.(7-B6-1; MabTech) diluted to 1 mg/ml in PBS + 1% bovine
serum albumin + 0.05% Tween was added. Incubation was
done at 4°C overnight. After washing, the plates were incu-
bated for 1 h at room temperature with 50 ml/well
avidine–alkaline phosphatase (Dakopatts, Glostrup,
Denmark) diluted 1:1000 in PBS + 0.05% Tween. After
washing, 50 ml/well substrate [p-nitrophenyl-phosphate
tablets (Sigma) 1 mg/ml in diethanolamine buffer, pH 9.8]
was added and the reaction was read at 405 nm in a spec-
trophotometer. To correct for the general low T-cell reactiv-
ity seen in RA PBMCs (Fig. 1a), the CII-induced interferon-g
production was expressed as a fraction of the PPD or killed
influenza virus-induced interferon-g production obtained in
parallel PBMC cultures.
Serum anticollagen type II detection by enzyme-linked
immunosorbent assay
ELISA plates (Maxisorp; NUNC S/A) were coated with
100 ml/well with native chick CII (Sigma) diluted to
5 mg/ml in ice-cold PBS overnight at 4°C. After blocking
with PBS + 1% bovine serum albumin and washing with
PBS + 0.05% Tween, 100 ml/well of a high-titre standard
serum (added in a dilution series) and the samples, diluted
at least 1:5 in PBS + 1% bovine serum albumin, were
added in duplicate and incubated for 2 h at room tempera-
ture. After washing, 100 ml of a biotinylated goat antihu-
man IgG antibody (Tago, Burlingame, CA, USA) diluted to
1 mg/ml in PBS + 1% bovine serum albumin was added
and incubated overnight at 4°C. The ELISA was devel-
oped as above. Elevated levels of IgG anti-CII were
defined as mean ± two standard deviations of sera from
39 healthy controls (> 9 U/ml). The standard serum was
arbitrarily defined as having 1500 U/ml.
Human leucocyte antigen genotyping
HLA-DR and HLA-DQ genotyping was performed utilizing
a polymerase chain reaction-based technique with
sequence-specific oligonucleotide probes hybridization
[25,26]. DRB1*01 subtypes were identified by allele-
specific polymerase chain reaction primers [27].
Statistical analysis
Nonparametric methods were used throughout the study.
Differences between groups were analyzed using the
Mann–Whitney U-test, and analyses for matched pairs
were performed using Wilcoxon’s signed-rank test. When
analyzing correlations, Spearman rank correlation was
used.  P < 0.05 was considered statistically significant.
Results
PBMCs from RA patients and healthy control individuals
were challenged in vitro with native and denatured CII,
and supernatants from these cultures were investigated
for interferon-g content. In both groups, an increased inter-
feron-g production was recorded after in vitro culture with
both native and denatured CII as compared with cultures
with no added antigen, giving a median stimulation index
with native CII of 4.6 for RA patients and 5.4 for healthy
control individuals, and with denatured CII of 2.9 for RA
patients and 3.0 for healthy control individuals. No differ-
ence in interferon-g production in response to CII could be
demonstrated between RA patients and healthy control
individuals (Fig. 1a). As control, PBMCs from 12 RA
patients and seven healthy control individuals were stimu-
lated with pepsin (10 mg/ml). No interferon-g induction
was evident with this stimulation (data not shown).
Parallel cultures were also stimulated with the standard
recall antigens PPD and killed influenza virus. These anti-
gens also induced the production of interferon-g in
PBMCs from both RA patients and healthy control
individuals, giving median stimulation indexes with PPD of
10.0 (RA patients) and 51.3 (healthy control individuals),
and with killed influenza virus of 12.3 (RA patients) and
25.7 (healthy control individuals). For both PPD and
influenza stimulations there was a significant difference
between the RA group and the healthy control group in
that the RA patients displayed a markedly lower respon-
siveness to PPD and to influenza (Fig. 1b).
In order to investigate whether the observed production of
interferon-g in response to stimulation with CII, PPD and
influenza was mediated by MHC class II-dependent T-cell
activation, blocking antibodies were added to the cell cul-
tures. As shown in Table 2 these antibodies inhibited the
CII as well as the PPD-induced and killed influenza virus-
induced interferon-g production. No such inhibitory effects
were observed after incubation with isotype-matched
control monoclonal antibodies.
As stated in the introduction to this report, the lower
responses to PPD and killed influenza virus in RA patients
than in healthy control individuals reflect a general down-
regulation of antigen-induced responsiveness of T cells
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Table 2
CII-induced interferon-g g response is major histocompatibility
complex (MHC) class II restricted
No ab Class II ab Control ab
CII 100 10 (6–22) 75 (66–125)
PPD 100 13 (8–32) 109 (63–123)
influenza 100 7 (4–15) 95 (68–125)
Peripheral blood mononuclear cells from two rheumatoid arthritis
patients and three healthy controls were stimulated with native
collagen type II (CII), influenza virus or purified protein derivative in the
presence of antibodies (ab) specific for major histocompatibility
complex-class II or isotype-matched control antibodies. Supernatants
were collected after 7 days of culture and the concentration of
interferon-g was analysed by enzyme-linked immunosorbent assay.
Values are expressed as median % (range) of cytokine present in
supernatants of which no antibodies were added.from RA patients [6–8]. That no difference between the
RA group and the control group was recorded in CII-
induced interferon-g production therefore indicates that
there may be an underlying increased specific and MHC
class II-dependent responsiveness to CII in the RA
patients, which is obscured by the general downregulation
of T-cell responsiveness. In order to address this possibil-
ity, we calculated the fraction between individual values
for the CII-induced interferon-g production and the PPD-
induced and killed influenza virus-induced interferon-g pro-
duction, and compared these fractions.
When compensating for the general T-cell hyporespon-
siveness in RA-derived T cells in this manner, using the
PPD response as the denominator, a highly significant
difference between the RA group and the healthy control
individuals was apparent after stimulation with both native
CII and denatured CII (Fig. 2a). Similar data were obtained
using killed influenza virus-stimulated interferon-g values as
the denominator, but no statistical difference between RA
patients and healthy control individuals could be deter-
mined for native CII (Fig. 2b).
We next investigated whether there was a difference
between patients with elevated serum levels of anti-CII
antibodies as compared with other RA patients with
regard to the T-cell response to CII. Analyzing uncompen-
sated interferon-g production in response to CII stimula-
tion revealed, contrary to our expectations, that RA
patients with high levels of anti-CII had lower interferon-g
responses to denatured CII compared with those of RA
patients with low levels of anti-CII (Fig. 4a). A similar ten-
dency, but not statistically significant, could also be
demonstrated using native CII. There was no difference in
the PPD-induced or killed influenza virus-induced inter-
feron-g responses between RA patients with high and low
anti-CII levels (data not shown).
The results obtained after compensating for the T-cell
hyporesponsiveness using PPD as the denominator
demonstrate that both the RA patients with low anti-CII
antibody levels and those with high levels had significantly
greater responses to native CII than did healthy control
individuals (Fig. 4b). For the group with low anti-CII levels
there was also a highly significant increased response to
denatured CII as compared with healthy control individuals,
which could not be observed for patients with high anti-CII
levels. Similar results were observed using influenza-
induced interferon-g as the denominator (data not shown).
We also correlated the responsiveness to CII to various
clinical parameters (C-reactive protein levels, presence of
erosions as measured by radiography, numbers of swollen
and tender joints, and disease duration). No correlations
between C-reactive protein, presence of erosions or
number of swollen joints and the compensated interferon-
g response to CII could be demonstrated; the only signifi-
cant association noted was a weak negative relationship
between number of tender joints and the PPD-compen-
sated CII-reactivity (P = 0.009,  rs = –0.46, data not
shown). The RA group with high levels of anti-CII had a
significantly higher number of swollen joints than the RA
group with low levels of anti-CII (P = 0.029, data not
shown). A positive correlation was noted between disease
duration and responsiveness to native or denatured CII
(compensated values; P = 0.036, rs = 0.33 for native CII
and P = 0.002, rs = 0.49 for denatured CII).
Finally, we compared the compensated interferon-g
response to denatured CII stimulation between RA
patients with different HLA genotypes. Of the RA patients
http://arthritis-research.com/content/2/1/075
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Figure 4
Rheumatoid arthritis (RA) patients with low levels of anticollagen type II
(CII) had a higher cellular reactivity to denatured CII compared with RA
patients with high levels of anti-CII. Production of interferon-g in RA
patients with high serum levels of anti-CII antibodies (n = 19) or low
anti-CII levels (n = 26) and healthy control individuals (n = 25) is
shown. In (a), interferon-g induction after stimulation with native or
denatured CII is shown. In (b), the CII response has been expressed
as a fraction of the purified protein derivative (PPD) response showing,
on the y axis, the quotient between the CII-induced interferon-g
production and the PPD-induced interferon-g production. Shaded
boxes represent RA patients with high serum levels of anti-CII, striped
boxes represent RA patients with low levels of anti-CII and open boxes
represent healthy control individuals. The box plots show the median
as a line and the 25th and 75th centiles limiting the box, with the 10th
and 90th centiles indicated with bars.included in this study, 13 were DRB1*0401 positive and
15 were DQ8 positive. Out of these patients, 12 were
DRB1*0401/DQ8 double positive. Of the healthy control
individuals, nine were DRB1*0401 positive and five were
DQ8 positive (four were not genotyped for HLA-DQ). Out
of these healthy control individuals, four were
DRB1*0401/DQ8 double positive. Highly significant dif-
ferences were evident, with HLA-DRB1*0401 patients
having higher CII responsiveness than patients lacking this
genotype (Fig. 3a). HLA-DQ8-positive patients also dis-
played a high responsiveness to CII as compared with
HLA-DQ8-negative RA patients (Fig. 3b). Similar results
were achieved using killed influenza virus as the denomi-
nator (P = 0.02 for HLA-DRB1*0401 and P = 0.01 for
HLA-DQ8). These associations between the relative T-cell
reactivity to denatured CII and HLA class II genotypes
were not seen in healthy control individuals. No significant
relationship between the analyzed HLA-DR or DQ haplo-
types and responsiveness to CII remained when the two
different groups of RA patients were analyzed separately.
No association was detected between serum levels of
anti-CII and the shared epitope (DRB1*0401 or
DRB1*0404).
Discussion
The major findings reported in this paper are as follows.
First, an increased interferon-g production in response to
in vitro stimulation with CII in RA patients as compared
with age-matched and sex-matched healthy control indi-
viduals when compensation was made for the general
hyporesponsiveness of RA patient PBMCs to nominal
antigens. Second, the response to CII was dependent on
MHC class II molecules, as demonstrated by the blockade
of the response with anti-MHC class II antibodies. Finally,
RA patients positive for the genotypes HLA-DRB1*0401
or HLA-DQ8 exhibited a higher interferon-g response than
did RA patients without these alleles.
The choice of interferon-g production as the parameter for
registration of the cellular response to CII was made both
from experience in mice immunized with CII and from multi-
ple sclerosis. In mice immunized with autologous CII, an
autoimmune arthritis-provoking response may occur that is
associated with in vivo antibody production to CII and with
CII-induced interferon-g production in vitro, but not with any
proliferative response to CII [9]. In multiple sclerosis patients,
in vitro production of T-cell cytokines such as interferon-g is
increased after in vitro stimulation with myelin antigens such
as myelin basic protein and myelin-oligodendrocyte glyco-
protein, despite the difficulties in detecting proliferative
responses towards these antigens [28].
Although there is much previous support for the choice of
interferon-g as a readout for T-cell responsiveness to anti-
gens, thus taking the potential partial anergy to CII into
account, no reports have previously systematically taken
the general T-cell hyporesponsiveness in RA into account
when investigating specific T-cell responses in this
disease. In the present study we used the T-cell
responses to PPD and killed influenza virus as reference
antigens for making this compensation. This was based on
the assumption that exposure to these antigens is similar
in age-matched and sex-matched groups of RA patients
and healthy control individuals. The concept of a general
hyporesponsiveness of RA T cells has been documented
in several previous reports in which both nominal antigens
[6–8] and mitogens [11–13] were used. Even though the
mechanisms behind this defective T-cell response are not
clear, it appears that the hyporesponsiveness is a feature
of the disease itself because it has been observed also in
patients who are not on disease-modifying antirheumatic
drug therapy [6]. The fact that a similar functional down-
regulation in RA PBMCs was obtained with both PPD and
killed influenza virus as reference antigens strengthens the
validity of our approach.
Both native and heat-denatured CII were used in the present
study on the basis that native and denatured CII may be
processed in different ways by antigen-presenting cells. As
shown in Figures 1a and 4a, native CII induced more inter-
feron-g than did denatured CII, indicating an important role
for the structure of CII in cellular stimulation. The difference
in the amount of interferon-g induced by native and dena-
tured CII might depend on differences in uptake or process-
ing of these structurally different CII molecules.
Proliferation in response to in vitro CII stimulation of cells
from both immunized animals and in human studies have
in some instances been found to be a response to conta-
minating pepsin in the CII preparation [29]. This possibility
was excluded in the present study by control experiments
that failed to demonstrate any interferon-g production in
response to pepsin (data not shown).
RA patients as well as healthy control individuals
responded with interferon-g production  in vitro when
PBMCs were stimulated with chick or human CII. It has
not directly been demonstrated that the interferon-g-pro-
ducing cells are T cells, but the fact that blocking of MHC
class II blocks the interferon-g response by RA PBMCs as
well as by control PBMCs indicates that this is indeed the
case. We also attempted to identify induction of a type 2
cytokine, but failed to detect interleukin-4 in CII stimulated
cultures using methods that are capable of detecting inter-
leukin-4 in cultures stimulated with a recall antigen.
We identified an association between the magnitude of
the interferon-g response to CII and HLA-DRB1*0401 and
HLA-DQ8 in the RA group, which is of obvious interest
because both these MHC class II alleles have been asso-
ciated with high responsiveness to CII in transgenic mice
that express these human MHC class II molecules
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82[14–16]. Thus far, susceptibility to RA has mainly been
associated with HLA-DRB1*0401 and with other MHC
class II molecules carrying the ‘shared epitope’ [30,31],
whereas it remains unclear whether HLA-DQ8 has an
independent association with RA. In in vitro studies of cel-
lular responses to CII in RA patients, some reports have
claimed that cellular reactivity to CII (measured as CII-
induced proliferation or production of factors capable of
stimulation of leucocyte functions) is associated with HLA-
DR4 [32–34]. Others, however, have not found this asso-
ciation [35,36]. Anti-CII-producing B cells have been
reported to be present in the joint [17,18] and have in
some instances been associated with HLA-DR4 [18,19].
It is difficult to separate the influences of HLA-DR4 and
HLA-DQ8 in studies of the association between MHC
class II alleles and RA or in in vitro associations between
cellular reactivity to CII and MHC class II alleles, because
of the strong linkage disequilibrium between DRB1*0401
and HLA-DQ8. Finally, it should be noted that the RA
patients in the present study were recruited in two differ-
ent ways; 19 patients were selected on the basis of their
high anti-CII antibody levels and 26 patients with low anti-
CII levels were randomly recruited from our outpatient
clinic. The HLA associations to cellular CII reactivity were
only seen when both groups were combined, probably
because of the rather low numbers of patients in each
group. It appears unlikely to us that the association
between HLA haplotype and CII-induced T-cell respon-
siveness seen in the combined group should be due to a
bias introduced by selection of patients with high anti-CII
levels for the following reasons: the high anti-CII group
had a lower responsiveness to denatured CII than the ran-
domly chosen group of RA patients; and there was no
association between anti-CII levels and shared epitope
(HLA-DRB1*0401 or HLA-DRB1*0404).
The interferon-g reactivity to CII seen in most individuals
implies that T-cell tolerance to CII is incomplete. The
finding that high cellular response to CII associates with
HLA-DRB1*0401 and HLA-DQ8 could mean that selec-
tion in thymus favours a T-cell repertoire containing T-cell
receptors with high specificity for some CII epitope(s).
Another explanation for the HLA-associated cellular
response to CII is that these class II molecules could be
able to present some immunodominant peptides more effi-
ciently than other class II molecules.
One recent study [37] has investigated CII-specific prolif-
erative responses and their relation to the presence of cir-
culating anti-CII antibodies in RA patients. That study
could not demonstrate a difference in proliferative
response to CII between RA patients and healthy control
individuals. In contrast to the present results, however, a
lower frequency of responsive RA patients without anti-CII
compared with that in RA patients with anti-CII was
recorded, which could not be explained by a difference in
disease-modifying antirheumatic drug therapy between
the two patient groups. This contradiction could be
explained by the definition of anergy, as suggested by
Mueller et al [38], that proliferative responses are lost
whereas effector functions are retained in anergized T
cells. Hence, T cells in RA patients without anti-CII might
be anergic in the proliferative aspect but are still able to
respond by cytokine production.
It has been shown by Cook et al [39] that levels of anti-CII
in serum of RA patients decreases over time. This ten-
dency was also apparent in the present study, but it was
not designed to address this question (data not shown).
We demonstrated a positive correlation between disease
duration and interferon-g response to CII, indicating that
the T-cell response to CII (expressed as a fraction of the
PPD-induced interferon-g response) increases with time.
As the PPD-induced interferon-g production decreases
with disease duration (data not shown), this implies that
general T-cell reactivity decreases gradually during the
course of RA. CII-induced interferon-g production remains
stable, however, and it increases when expressing the CII
cellular reactivity as a fraction of the PPD cellular reactiv-
ity. Consequently, although humoral CII reactivity
decreases with time [39], cellular CII reactivity increases.
It is thus plausible that serum antibody levels to CII consti-
tute a relatively poor mirror of T-cell responsiveness to CII.
Because anti-CII antibodies and T cells reactive with CII
may synergize in causing arthritis [40] (at least in rodents),
there is an obvious need for further detailed parallel
studies of B-cell and T-cell reactivity to CII in RA, taking
the fine specificity (not addressed in the present study)
into account.
In conclusion, CII, a major autoantigen candidate in RA, can
elicit an interferon-g response in vitro that is associated with
HLA-DRB1*0401 and HLA-DQ8 in RA patients. The
present study, with a partly new methodological approach
to a classical problem in RA, has provided some additional
support to the notion that CII may be a target autoantigen of
importance for a substantial group of RA patients. Contin-
ued efforts to identify mechanisms behind the general
hyporesponsiveness to antigens in RA, as well as the mech-
anisms behind the potential partial anergy to CII, may
provide us with better opportunities to study the specificity
and pathophysiological relevance of anti-CII reactivity in RA.
Acknowledgement
We thank Associate Professor Robert A Harris for linguistic advice.
References
1. Stastny P, Fernandez-Vina M, Cerna M, et al: Sequences of HLA
alleles associated with arthritis in adults and children. J Rheumatol
Suppl 1993, 37:5–8.
2. Wooley PH, Luthra HS, O’Duffy JD, et al: Anti-type II collagen anti-
bodies in rheumatoid arthritis. The influence of HLA phenotype.
Tissue Antigens 1984, 23:263–269.
http://arthritis-research.com/content/2/1/075
833. Morgan K, Clague RB, Reynolds I, Davis M: Antibodies to type II col-
lagen in early rheumatoid arthritis. Br J Rheumatol 1993, 32:
333–335.
4. Clague RB, Morgan K, Reynolds I, Williams HJ: The prevalence of
serum IgG antibodies to type II collagen in American patients with
rheumatoid arthritis. Br J Rheumatol 1994, 33:336–338.
5. Trentham DE, Townes AS, Kang AH: Autoimmunity to type II colla-
gen an experimental model of arthritis. J Exp Med 1977, 146:
857–868.
6. Emery P, Panayi GS, Nouri AM: Interleukin-2 reverses deficient cell-
mediated immune responses in rheumatoid arthritis. Clin Exp
Immunol 1984,  57:123–129.
7. Seitz M, Napierski I, Kirchner H: Depressed PPD and tetanus toxoid
presentation by monocytes to T lymphocytes in patients with
rheumatoid arthritis: restoration by interferon gamma. Rheumatol
Int 1988, 8:189–196.
8. Verwilghen J, Vertessen S, Stevens EA, Dequeker J, Ceuppens JL:
Depressed T-cell reactivity to recall antigens in rheumatoid arthri-
tis. J Clin Immunol 1990, 10:90–98.
9. Malmstrom V, Michaelsson E, Burkhardt H, et al: Systemic versus
cartilage-specific expression of a type II collagen-specific T-cell
epitope determines the level of tolerance and susceptibility to
arthritis. Proc Natl Acad Sci USA 1996, 93:4480–4485.
10. Arnett FC, Edworthy SM, Bloch DA, et al: The American Rheuma-
tism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 1988, 31:315–324.
11. Silverman HA, Johnson JS, Vaughan JH, McGlamory JC: Altered lym-
phocyte reactivity in rheumatoid arthritis. Arthritis Rheum 1976, 19:
509–515.
12. Mirza NM, Relias V, Yunis EJ, Pachas WN, Dasgupta JD: Defective
signal transduction via T-cell receptor-CD3 structure in T cells
from rheumatoid arthritis patients. Hum Immunol 1993, 36:91–98.
13. Allen ME, Young SP, Michell RH, Bacon PA: Altered T lymphocyte sig-
naling in rheumatoid arthritis. Eur J Immunol 1995, 25:1547–1554.
14. Rosloniec EF, Brand DD, Myers LK, et al: Induction of autoimmune
arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immuniza-
tion with human and bovine type II collagen. J Immunol 1998, 160:
2573–2578.
15. Nabozny GH, Baisch JM, Cheng S, et al: HLA-DQ8 transgenic mice
are highly susceptible to collagen-induced arthritis: a novel model
for human polyarthritis. J Exp Med 1996, 183:27–37.
16. Andersson EC, Hansen BE, Jacobsen H, et al.: Definition of MHC
and T cell receptor contacts in the HLA-DR4 restricted immuno-
dominant epitope in type II collagen and characterization of colla-
gen-induced arthritis in HLA-DR4 and human CD4 transgenic
mice. Proc Natl Acad Sci USA 1998, 95:7574–7579.
17. Tarkowski A, Klareskog L, Carlsten H, Herberts P, Koopman WJ:
Secretion of antibodies to types I and II collagen by synovial
tissue cells in patients with rheumatoid arthritis. Arthritis Rheum
1989, 32:1087–1092.
18. Ronnelid J, Lysholm J, Engstrom-Laurent A, Klareskog L, Heyman B:
Local anti-type II collagen antibody production in rheumatoid
arthritis synovial fluid. Evidence for an HLA-DR4-restricted IgG
response. Arthritis Rheum 1994, 37:1023–1029.
19. Banerjee S, Luthra HS, Moore SB, O’Fallon WM: Serum IgG anti-
native type II collagen antibodies in rheumatoid arthritis: associa-
tion with HLA DR4 and lack of clinical correlation. Clin Exp
Rheumatol 1988,  6:373–380.
20. Huang YH, Ronnelid J, Frostegard J: Oxidized LDL induces
enhanced antibody formation and MHC class II-dependent IFN-
gamma production in lymphocytes from healthy individuals. Arte-
rioscler Thromb Vasc Biol 1995, 15:1577–1583.
21. Coulie PG, Van Snick J: Enhancement of IgG anti-carrier responses
by IgG2 anti-hapten antibodies in mice. Eur J Immunol 1985, 15:
793–798.
22. Hohlfeld R, Conti-Tronconi B, Kalies I, Bertrams J, Toyka KV:
Genetic restriction of autoreactive acetylcholine receptor-
specific T lymphocytes in myasthenia gravis. J Immunol 1985,
135:2393–2399.
23. Klareskog L, Forsum U, Scheynius A, Kabelitz D, Wigzell H: Evidence
in support of a self-perpetuating HLA-DR-dependent delayed-type
cell reaction in rheumatoid arthritis. Proc Natl Acad Sci USA 1982,
79:3632–3636.
24. McHugh S, Deighton J, Rifkin I, Ewan P: Kinetics and functional
implications of Th1 and Th2 cytokine production following activa-
tion of peripheral blood mononuclear cells in primary culture. Eur
J Immunol 1996, 26:1260–1265.
25. Sanjeevi CB, Hook P, Landin-Olsson M, et al: DR4 subtypes and
their molecular properties in a population-based study of
Swedish childhood diabetes. Tissue Antigens 1996, 47:275–283.
26. Sanjeevi CB, Hagopian WA, Landin-Olsson M, et al: Association
between autoantibody markers and subtypes of DR4 and DR4-DQ
in Swedish children with insulin-dependent diabetes reveals
closer association of tyrosine pyrophosphatase autoimmunity
with DR4 than DQ8. Tissue Antigens 1998; 51:281–286.
27. Olerup O, Zetterquist H: HLA-DR typing by PCR amplification with
sequence-specific primers (PCR-SSP) in 2 hours: an alternative to
serological DR typing in clinical practice including donor-recipient
matching in cadaveric transplantation. Tissue Antigens 1992, 39:
225–235.
28. Wallstrom E, Khademi M, Andersson M, et al: Increased reactivity to
myelin oligodendrocyte glycoprotein peptides and epitope
mapping in HLA DR2(15)+ multiple sclerosis. Eur J Immunol 1998,
28:3329–3335.
29. Vingsbo C, Larsson P, Andersson M, Holmdahl R: Association of
pepsin with type II collagen (CII) breaks control of CII autoimmu-
nity and triggers development of arthritis in rats. Scand J Immunol
1993, 37:337–342.
30. Stastny P, Fink CW: HLA-Dw4 in adult and juvenile rheumatoid
arthritis. Transplant Proc 1977, 9:1863–1866.
31. Gregersen PK, Silver J, Winchester RJ: The shared epitope hypoth-
esis. An approach to understanding the molecular genetics of
susceptibility to rheumatoid arthritis. Arthritis Rheum 1987, 30:
1205–1213.
32. Solinger AM, Stobo JD: Immune response gene control of T depen-
dent reactivity to collagen in man. Adv Exp Med Biol 1982, 150:
141–155.
33. Solinger AM, Bhatnagar R, Stobo JD: Cellular, molecular, and
genetic characteristics of T cell reactivity to collagen in man. Proc
Natl Acad Sci USA 1981, 78:3877–3881.
34. Solinger AM, Stobo JD: Regulation of immune reactivity to collagen
in human beings. Arthritis Rheum 1981, 24:1057–1064.
35. Kammer GM, Trentham DE: HLA-DR4 is not a requisite for autoim-
munity to collagen in rheumatoid arthritis. Arthritis Rheum 1984,
27:489–494.
36. Strom H, Al-Balaghi S, Moller E: No demonstrable association
between HLA DR4 and in vitro collagen reactivity as determined
by the production of leukocyte inhibition factor. Tissue Antigens
1984, 24:174–183.
37. Snowden N, Reynolds I, Morgan K, Holt L: T cell responses to
human type II collagen in patients with rheumatoid arthritis and
healthy controls. Arthritis Rheum 1997, 40:1210–1218.
38. Mueller DL, Jenkins MK, Schwartz RH: Clonal expansion versus
functional clonal inactivation: a costimulatory signalling pathway
determines the outcome of T cell antigen receptor occupancy.
Annu Rev Immunol 1989, 7:445–480.
39. Cook AD, Rowley MJ, Mackay IR, Gough A, Emery P: Antibodies to
type II collagen in early rheumatoid arthritis. Correlation with
disease progression. Arthritis Rheum 1996, 39:1720–1727.
40. Taylor PC, Plater-Zyberk C, Maini RN: The role of the B cells in the
adoptive transfer of collagen-induced arthritis from DBA/1 (H-2q)
to SCID (H-2d) mice. Eur J Immunol 1995, 25:763–769.
Authors’ affiliations: Louise Berg (Department of Medicine, Unit of
Rheumatology, Karolinska Hospital, Stockholm, Sweden), Johan
Rönnelid (Department of Clinical Immunology, University Hospital,
Uppsala, Sweden), Carani B Sanjeevi (Molecular Immunogenetics
Group, Department of Molecular Medicine, Karolinska Hospital,
Stockholm, Sweden), Jon Lampa and Lars Klareskog (Rheumatology
Unit, Karolinska Hospital, Stockholm, Sweden)
Correspondence: Louise Berg, Department of Medicine, Unit of
Rheumatology, Karolinska Hospital, CMM L8:04, 171 76 Stockholm,
Sweden. Tel: +46 8 5177 56 05; fax: +46 8 5177 55 62;
e-mail: louise.berg@cmm.ki.se
Arthritis Research    Vol 2 No 1 Berg et al
84